13-Hydroxylergotrile, also known as 2-chloro-6-methyl-13-hydroxyergoline-8β-acetonitrile, is a dopamine receptor agonist of the ergoline family. It is an active metabolite of the never-marketed antiparkinsonian agent lergotrile (LY-79907). The drug has been found to be 100-fold more potent as a dopamine receptor agonist than lergotrile itself in vitro. 13-Hydroxylergotrile was first described in the scientific literature by 1978.
See also Substituted ergoline 13-Hydroxy-LSD
References